[Development of new molecular target drug].
Tamura
Kenji
K
Breast and Medical Oncology Division, Outpatient Clinic, National Cancer Center Hospital, Tokyo, Japan
D000906:Antibodies / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
D000906:Antibodies; C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D020794:Receptor Protein-Tyrosine Kinases